Metabolic profiling of female tg2576 mouse brains provides novel evidence supporting intranasal low-dose pioglitazone for long-term treatment at an early stage of alzheimer’s disease
10.3390/biomedicines8120589
Saved in:
Main Authors: | Wong, L.R., Wong, P., Ho, P.C.-L. |
---|---|
Other Authors: | PHARMACOLOGY |
Format: | Article |
Published: |
MDPI AG
2021
|
Subjects: | |
Online Access: | https://scholarbank.nus.edu.sg/handle/10635/196316 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
NOSE-TO-BRAIN DELIVERY OF MITOCHONDRIA TARGETING DRUGS FOR THE TREATMENT OF ALZHEIMER'S DISEASE: PHARMACOKINETIC AND NEUROPHENOTYPING EVALUATION
by: WONG LING RONG
Published: (2019) -
EXPLORATION OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA AGONIST IN ALZHEIMER'S DISEASETHERAPY - A THERAPEUTIC ENIGMA
by: CHANG KAI LUN
Published: (2015) -
Growth dynamics of human leiomyoma cells and inhibitory effects of the peroxisome proliferator-activated receptor-γ ligand, pioglitazone
by: Loy, C.J., et al.
Published: (2011) -
Intranasal delivery of self-assembly insulin nanocomplexes based on surface modified trimethyl chitosan
by: Anchalee Jintanapattanakit
Published: (2023) -
Tailoring midazolam-loaded chitosan nanoparticulate formulation for enhanced brain delivery via intranasal route
by: Shrestha, N., et al.
Published: (2021)